Isotretinoin is safe for most people when monitored properly, but it carries real risks that vary widely in severity. The most common side effects, like dry skin and chapped lips, are temporary and manageable. The most serious risk, severe birth defects during pregnancy, is absolute and requires strict prevention measures. Everything else falls on a spectrum between those extremes, and understanding where each risk lands helps you make an informed decision.
How Isotretinoin Works
Isotretinoin targets the oil-producing glands in your skin. It slows the growth of the cells that line these glands, triggers some of those cells to die off, and dramatically reduces oil production. This is why it works so well for severe acne, and it’s also why many of its side effects involve dryness throughout your body. The cell death it causes in oil glands uses a different pathway than other vitamin A-based medications, which partly explains why isotretinoin is uniquely effective and why its effects often persist long after you stop taking it.
Side Effects You Should Expect
Some side effects are so common they’re essentially guaranteed. A meta-analysis pooling thousands of patients found that about 49% developed dry skin and 42% experienced cheilitis (cracked, peeling lips). Joint pain affected roughly 17% of patients, and general muscle or skeletal discomfort hit about 13%. These side effects tend to be dose-dependent: higher doses cause more dryness and more aches.
Most of these resolve after treatment ends. Lip balm, moisturizer, and occasional pain relievers are the typical management tools. Your skin and lips will likely feel noticeably dry within the first few weeks, and this continues throughout treatment. For most people, these side effects are annoying rather than dangerous.
Eye Dryness and Meibomian Gland Changes
Isotretinoin affects the small oil glands in your eyelids (meibomian glands) the same way it affects oil glands elsewhere. During treatment, these glands shrink and produce less of the oily film that keeps your tears from evaporating, leading to dry, irritated eyes. Research shows these changes are largely reversible after stopping the drug, but with a caveat: gland function and eye comfort scores improved significantly after treatment ended, yet in studies they didn’t fully return to pre-treatment levels. The practical takeaway is that most people’s eyes recover, but some may notice mildly drier eyes than before, particularly if they were already prone to dry eye.
Pregnancy: The One Absolute Risk
Isotretinoin causes severe, life-threatening birth defects. This is not a theoretical risk or a rare complication. It is a certainty if a developing fetus is exposed during critical periods of pregnancy. The defects affect the brain, heart, and face.
Because of this, every isotretinoin prescription in the United States goes through the iPLEDGE program, a federal risk management system. If you can become pregnant, you must have a pregnancy test in a medical setting before starting treatment. During and after treatment, your prescriber may allow you to use at-home pregnancy tests, a change the FDA approved in 2026 to reduce the burden of monthly clinic visits. Two forms of contraception are required throughout treatment and for a period after stopping. If you cannot become pregnant, the requirements are lighter: counseling at enrollment, with no monthly documentation needed.
Mental Health Concerns
The link between isotretinoin and depression has been debated for decades, and the best available evidence is reassuring. A meta-analysis of 25 studies covering more than 1.6 million participants found that isotretinoin was not associated with an increased risk of psychiatric disorders overall. The one-year rates of completed suicide, suicide attempts, suicidal thoughts, and self-harm were each below 0.5% among isotretinoin users. The one-year rate of depression was about 3.8%.
Perhaps more telling, isotretinoin users were actually less likely than nonusers to attempt suicide two to four years after treatment. This likely reflects the psychological benefit of clearing severe acne, which itself causes significant depression and social withdrawal. Still, severe acne patients are a vulnerable population regardless of treatment, so paying attention to mood changes during treatment remains sensible.
Liver and Blood Lipid Effects
Isotretinoin can raise liver enzymes and blood lipid levels, which is why blood work is part of the treatment process. Up to 15% of patients see some elevation in liver enzymes, but significant elevations requiring the drug to be stopped are rare, occurring in fewer than 1% of cases. Clinically apparent liver injury with symptoms like jaundice is exceedingly rare. Isotretinoin carries a lower liver risk than several other vitamin A-related medications.
The most common lab abnormality is elevated LDL cholesterol, affecting roughly 44% of patients in one study by the second month of treatment. Triglycerides can also spike. For generally healthy patients, recent evidence suggests that checking lipids and liver function at baseline and again at peak dosage may be sufficient, though European guidelines recommend testing before treatment, at one month, and every three months. Your dermatologist will determine the schedule based on your health history. Fewer than 2% of patients experience liver enzyme elevations severe enough to be clinically concerning.
Bone Health in Younger Patients
Isotretinoin can affect bones, and the concern differs by age group. In children and adolescents, high doses carry a risk of premature closure of growth plates, which could theoretically limit final height. In adults on long-term therapy, there’s an increased tendency to develop bony overgrowths along the spine and other skeletal changes. For the typical acne patient taking a standard course lasting five to seven months, these risks are minimal. They become more relevant for people who need repeated or prolonged courses.
The Inflammatory Bowel Disease Question
Whether isotretinoin increases the risk of inflammatory bowel disease (IBD) has been studied extensively, and the answer is nuanced. A 2016 meta-analysis of six studies found no correlation. However, more recent large-scale studies have identified a small but statistically significant association. A nationwide study in South Korea found that isotretinoin users had about a 20% higher odds of developing IBD compared to nonusers. The association was present for both ulcerative colitis and Crohn’s disease, and it appeared to strengthen with longer use, higher cumulative doses, and more time since the first exposure.
A 20% increase in relative risk sounds alarming, but context matters. IBD is uncommon in the general population, so a 20% increase in a small baseline risk still yields a small absolute risk. Earlier studies found short-term increases in IBD risk (around a six-month window after exposure) that didn’t persist with longer follow-up. This is an area where the evidence is genuinely mixed, and the size of any real effect is likely modest.
Cumulative Dose and Relapse
How much isotretinoin you take over your entire course matters for long-term results. Patients who reached a cumulative dose of 220 mg/kg or higher had a relapse rate of about 27%, compared to 47% for those who received less. Higher cumulative doses significantly reduced the chance of needing retreatment at one year without increasing side effects. This is why dermatologists calculate your total dose based on body weight and adjust the treatment length accordingly, sometimes extending a course at a lower daily dose rather than cutting it short.
Putting the Risks in Perspective
Isotretinoin is the most effective treatment available for severe or treatment-resistant acne, and for many people it produces lasting clearance after a single course. Its side effect profile is well-characterized after four decades of use. The temporary effects (dryness, joint aches, elevated blood lipids) are common but manageable. The serious risks (birth defects, rare liver injury) are either preventable with proper precautions or genuinely uncommon. The feared psychiatric effects have not held up under large-scale population studies. The IBD link exists in some data but remains small in absolute terms. For most patients with acne severe enough to warrant it, the benefit of treatment outweighs the risks considerably.